Reported financial and operating results for the fourth quarter and full-year ended December 31, 2025. Topline data from the Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) is now anticipated in the second half of 2026, a delay to allow for data maturation, longitudinal and translational assessments, characterization of durability, and dose optimization. Results from the healthy volunteer study of its next-generation STAT3 inhibitor, TTI-109, remain on track for the second quarter of 2026. Additional analysis from the REVERT IPF Phase 2 trial demonstrated that TTI-101 was associated with a 9.4% baseline-weighted reduction in fibrosis score compared to 2.4% for placebo, and a 4.5-fold greater decline in IL-6. The cash runway is expected to be sufficient to fund operations into the fourth quarter of 2026 after clinical readouts. Net loss for the fourth quarter of 2025 was $7.3 million, an improvement from $12.7 million for the comparable period in 2024. Full-year 2025 net loss was $18.2 million, an improvement from $29.4 million for the full year 2024.